• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Healthcare·MCOV-B.ST
Share

Medicover AB Stocks

SEK 238.5Last Updated 09.09.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

SEK 3.82B

SEK 238.5
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Medicover AB (publ), established in Stockholm, Sweden in 1995, operates as a comprehensive provider of healthcare and diagnostic services throughout a dozen countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. The company's operations are distinctly categorized into two segments: Healthcare Services and Diagnostic Services. Within its Diagnostic Services arm, Medicover performs an extensive array of laboratory analyses. These span various specialties, encompassing tests for allergies and autoimmune conditions, infectious agents (bacteriology, parasitology, microbiology), biochemical and immunological markers, blood grouping and transfusion requirements, tumor detection, clinical chemistry, cellular and tissue pathology (cytology, haematology, histopathology), human genetics, hygiene, molecular biology, and pharmacological/toxicological screenings. This substantial diagnostic infrastructure includes 97 clinical laboratories, 733 blood collection points, and 26 specialized clinics, operational across 10 of its countries of presence. Complementing this, the Healthcare Services division features a broad network comprising 117 medical clinics, 20 fertility centers, 52 dental practices, 25 hospitals, and 25 fitness facilities. Medicover caters to a diverse clientele, serving corporate clients, private individuals, direct patients, and public sector payers.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, r

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of MCOV-B.ST is 260 and suggests 8.82% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommend

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.09.2026 18:37

U.S. stocks jumped more than 1% following the release of inflation data

11.09.2026 17:37

Inflation in the U.S. in August came in slightly above expectations. What can we expect from the Fed now?

11.09.2026 17:24

"A Recipe for Volatility": Why BofA Sees Risks in Market Calm

11.09.2026 15:00

Uber's CEO Invested $10 Million in the Company's Shares, Which Had Fallen in Price

11.09.2026 13:30

An investor from "Shorting" advised buying wine amid the dollar's decline

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026